In this episode of Topical Conversations, Dr Stephen Lewellis provides an insightful overview of the evolving landscape of dermatology devices and treatments to watch in 2025. Sharing his personal insights and experiences, Dr Lewellis highlights how these innovations can enhance patient outcomes and help dermatologists distinguish their practice by offering unique and forward-thinking options that patients may not encounter elsewhere. 

AviClear for acne 

Dr Lewellis begins by discussing AviClear, a 1726-nanometer laser device FDA cleared for treating acne of all severities. He highlights its best use cases, including moderate to severe inflammatory acne and patients who cannot or do not wish to take isotretinoin. 

• Treatment overview: Three treatments over 2 months with optimal results typically appearing 6 to 12 months post-treatment 
• Patient counseling: Emphasize patience and realistic expectations for long-term improvement 
• Cost consideration: Though not covered by insurance, it may be more affordable than isotretinoin in some cases 

Dr Lewellis advises dermatologists to consider AviClear as part of their practice or refer patients to trusted colleagues who offer this treatment to provide comprehensive care. 

excel V+ Plus for versatile needs 

The excel V+ device features the Laser Genesis treatment mode, which uses 532- or 1064-nanometer lasers to induce dermal heating. 

• Treatment benefits: Improved complexion, reduced pore size, and some acne improvement with minimal downtime 
• Expectations: While optimal results require 6 to 8 treatments, even 1 to 2 sessions can provide improvement 
• Applications: Beyond aesthetics, excel V+ can treat rosacea, inflammatory acne, and more, making it a versatile addition to a dermatology practice 

Swift for refractory warts 

Swift uses focused microwave energy to treat warts, especially plantar warts, by inducing a heat response that stimulates an immune reaction against the virus. 

• Advantages: Less painful than cryosurgery with no post-treatment wound formation 
• Key use case: Can be effective for refractory warts across the body

 Dr Lewellis notes that Swift is a niche offering that can help dermatologists stand out in their communities. 

YCANTH for molluscum contagiosum 

While not a device, YCANTH is a standardized form of cantharidin for molluscum contagiosum. 

• Treatment highlights: Reliable, controlled results with treatments every 3 weeks as needed 
• Controversy: While compounded cantharidin remains an option, consistency and robust data make YCANTH worth considering for patients 

Setting your practice apart 

Dr Lewellis concludes by advising that incorporating innovative devices and treatments such as AviClear, excel V+, and Swift, along with in-office options like YCANTH, represents an opportunity for dermatologists to differentiate their practices in 2025. These technologies offer cutting-edge solutions that can improve patient outcomes and expand treatment options. Exploring and integrating these advancements can help establish a practice as a leader in forward-thinking dermatologic care, enhancing both patient satisfaction and professional reputation within the community.